Vimarsana
Biggest News Aggregation in the World

Page 7 - Gregory Bell News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Gregory Bell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Gregory Bell Today - Breaking & Trending Today

Attralus Receives FDA and EMA Orphan Designation for AT-01 - Vimarsana News

Attralus Receives FDA and EMA Orphan Designation for AT-01

SAN FRANCISCO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to...

Strong Medicine: Using Investment Treaties to Mitigate Foreign Regulatory Risk in the Life Sciences | White & Case LLP - Vimarsana News

Strong Medicine: Using Investment Treaties to Mitigate Foreign Regulatory Risk in the Life Sciences | White & Case LLP

The COVID-19 pandemic has accelerated the globalization of the life sciences industry, driving cross-border collaborations to develop urgently needed treatments, scale up manufacturing...

Attralus Announces New Clinical Data in ATTR CM and AL With AT-01 (Iodine (I-124) Evuzamitide), a Novel Amyloid-Specific Imaging Agent - Vimarsana News

Attralus Announces New Clinical Data in ATTR CM and AL With AT-01 (Iodine (I-124) Evuzamitide), a Novel Amyloid-Specific Imaging Agent

AT-01 shows increased LV uptake and LV amyloid activity in all cardiac ATTR and AL subjects, but in none of the controls (100% accuracy) AT-01 demonstrates

Attralus Announces New Clinical Data in ATTR CM and AL With - Vimarsana News

Attralus Announces New Clinical Data in ATTR CM and AL With

AT-01 shows increased LV uptake and LV amyloid activity in all cardiac ATTR and AL subjects, but in none of the controls (100% accuracy)AT-01 demonstrates...

Attralus to Present New Data on Its Amyloidosis Portfolio at the 2022 International Symposium on Amyloidosis - Vimarsana News

Attralus to Present New Data on Its Amyloidosis Portfolio at the 2022 International Symposium on Amyloidosis

Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today